Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 356

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 356
---
 145 Adelaide Street West, Toronto ON M5H 4E5, Canada.

    (10)
    None of the directors
    of that board of directors has sole voting or dispositive power with respect to the shares of Common Stock held by Motif Pharmaceuticals
    Ltd. The principal executive office of Motif Pharmaceuticals Ltd. is 25 and 28 North Wall Quay, Dublin 1, Ireland.

    (11)
    Ezra Friedberg has
    sole voting and dispositive power over the shares held by Balmoral. The principal executive office of Balmoral is 106 Court
    Road, Suite 202, Baltimore, MD 21208.

    (12)
    Ruth Friedman has
    sole voting and dispositive power over the shares held by AME Equities LLC. The principal executive office of AME Equities
    LLC is 3012 Luke Crossing Drive, Charlotte, NC 28226.

    (13)
    None of the directors
    of that board of directors has sole voting or dispositive power with respect to the shares of Common Stock held by Aperture
    Healthcare Ventures Ltd. The principal executive office of Aperture Healthcare Ventures Ltd. is 970 Lawrence Ave W. Suite
    904, Toronto, ON M6A 3B6, Canada.

    (14)
    Darwin Richardson
    has sole voting and dispositive power over the shares held by Benuvia. The principal executive office of Benuvia is 3950 N.
    Mays Street Round Rock, TX 78665.

Securities
Authorized for Issuance under Equity Compensation Plans

    Plan
    Category
     
    Number
    of
    Securities to Be 
    Issued upon 
    Exercise of 
    Outstanding 
    Options, Warrants 
    and Rights (2)

    Weighted
    Average
    Exercise Price of 
    Outstanding 
    Options, 
    Warrants and 
    Rights (2)

    Number
    of Securities 
    Remaining Available for 
    Future Issuance under 
    the Plan (excluding 
    securities reflected in 
    column (a) (2))

    (a)

    (b)

    (c)

    Equity
    compensation plans approved by security holders (1)

    925,449

    $
    5.95

    1,018,995

    Equity
    compensation plans not approved by security holders

    Total

    1,018,